BIO 2025 brings pharma, biotech, and policy leaders together to tackle industry challenges. Follow our coverage on AI, vaccines, cell & gene therapy, and key discussions from health officials.

Garden Fae is a series of playful ambient aerial performances in the park inspired by embodying the spirit of the natural landscape.

Courtesy of IX Arts Foundation. The Fae Festival is an enchanted urban Renaissance Faire in the heart of Charlottesville. On Saturday, June 28, 2025, from 3 to 9 p.m. and Sunday, June 29, 2025 ...

Lead ESPN NBA play-by-play announcer Mike Breen addressed reports that the network might replace analyst Doris Burke next season.

Company to host a conference call to discuss results at 8:00am EDT on June 30, 2025 Boca Raton, Florida, June 26, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a ...

Bootstrap Bio has hired a chief science officer, opened a lab and sought seed funding to edit human cells that can be passed to future generations ...

Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last ...

Sunday night in Oklahoma City will be the first finals Game 7 since the “Blocked by James” game nine years ago, and Breen will be back on the lead call. It will be the fifth time in Breen’s ...

-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis ...

Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune ...

Harvard researcher Kseniia Petrova is indicted on three federal charges for allegedly smuggling frog embryos into the U.S., potentially facing up to 20 years in prison for the violations.

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset & $175M Private Placement ...